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P1. MATRIX-PET: A NOVEL PET DETECTOR CONCEPT BASED 
ON LARGE BLOCKS OF ORGANIC SCINTILLATORS
P Moskal, T Bednarski, A Heczko, M Kajetanowicz, Ł Kapłon, A Kochanowski, 
G Konopka-Cupiał, G Korcyl, W Krzemień, K Łojek, W Migdał, M Molenda, Sz Niedźwiecki, 
P Salabura, M Silarski, A Słomski, J Smyrski, Z Rudy, J Zdebik, M Zieliński.
Jagiellonian University, Cracow, Poland
Matrix-PET is a novel detector solution for the Positron Emission Tomography. It is one of the 
two methods which is developed at present at the Jagiellonian University [1]. The detector 
idea is a subject of a patent application [2]. Novelty of the concept lies in using the large 
and thick organic scintillators blocks as a detector of gamma quanta instead of crystal scin-
tillators used in current commercial PET scanners. Its uniqueness constitutes the solution 
of light collection allowing for the conversion to the electric signal of direct light. The idea 
is demonstrated schematically in Figure 1. This method allows to achieve a time resolution 
which is not affected by the deformation of light pulses due to reflections at scintillators sur-
faces. Such PET detector would consist of organic scintillator plates. The plates  could be 
set in many ways so as to cover the whole body of the patient, for example as it is shown 
in Figure 2. The measurement of time and amplitude of light signals is carried out by pho-
tomultipliers matrix arranged around the chamber. The interaction point within the plane of 
the plate can be reconstructed based on both: (i) the distribution of time of the signals from 
photomultipliers and (ii) distribution of amplitudes of the recorded signals. Such solution 
enables also determination of the depth at which the gamma quantum has been absorbed 
(DOI)  on the basis of the distribution of amplitudes of signals from photomultipliers which 
can be arranged also on front and back sides. This feature allows to use thick plates without 
worsening of spatial resolution due to “the DOI problem” occurring in the current PET tomo-
graphs. Enlargement of the thickness, and high acceptance, enables efficient detection of 
gamma quanta using organic plastic scintillators, which are characterized by excellent time 
resolution . This solution would also enable effective usage of the TOF method permitting the 
determination of the annihilation point along the line-of-response based on the time difference 
in reaching the different scintillation plates by the gamma quanta. Polymer scintillators allow to 
obtain the time resolution better than 100 ps compared to 600 ps achievable in a current PET 
Figure 1. Principle of light collection in the Matrix-PET
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scanners. Such accuracy of TOF determination may significantly improve the sensitivity (image 
contrast) which increases inversely proportional with the time resolution and directly proportional 
to the size of the examined object [3]. 
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Figure 2. One of the possible arrangement of scintillation plates for the diagnostic chamber of matrix-PET. The 
location of quantum reaction in a plate plane may be determined with three independent methods based on the 
(i) amplitude of the signals from the upper layer (U), (ii) from amplitudes of signals from front (F) and back (B), 
and left (L) and right (R) photomultipliers and (iii) based on time differences of photomultiplier signals from 
the front and rear layers and left and right photomultimpliers. The final result may be taken as the average 
weighted with appropriate measurement uncertainties
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P2. THE ROLE OF 18FDG-PET IN STAGING AND FOLLOW-UP 
OF ADOLESCENT NON-HODGKIN LYMPHOMA (CASE REPORT)
D Cich, Z Tomiskova, I Makaiova, S Kovacova 
Clinic of Nuclear Medicine, Oncological Institute of St. Elizabeth, Bratislava, Slovakia
Aim: Non-Hodgkin lymphomas in childhood and adolescence are almost exclusively from the 
group of high- grade lymphomas and according to WHO classification there are four main 
subgroups: lymphoblastic lymphoma, Burkitt lymphoma, diffuse large B-cell lymphoma and 
anaplastic large cell lymphoma. Exact staging has critical importance in the stratification into risk 
groups and treatment decision necessary to achieve optimal response and cure. We present 
the clinical value of FDG-PET for staging, monitoring therapy response and post-therapeutic 
surveillance in adolescent patient with NHL. 
Methods: Whole-body PET with 18F-FDG was performed according to standard protocol, in 
our case one patient with zhistologically proven Burkitt lymphoma. Patient-female was 16-year 
old at the time of confirmation of diagnosis. FDG-PET examinations were performed between 
March 2006 and Feb. 2011, overall 13 PET scans, with comparison SUVmax ratio in order to 
monitor therapy response. 
Results: The first control FDG-PET after first-line chemotherapy (5 cycles) reported non-response 
to therapy and changed into more aggressive strategy. Further PET examinations during follow-up 
revealed two recurrences atypical in breast. After third-line chemotherapy was achieved complete 
metabolic remission, which continues till now.
Conclusions: Overall survival rate in malignant lymphomas in childhood and adolescence have 
markedly improved during last years. Several reports have been indicating the usefulness of 
FDG-PET in pediatric Hodgkin lymphoma, however, that in pediatric Non-Hodgkin lymphoma 
is not fully investigated. Current international guidelines for response criteria incorporated PET 
and PET/CT as routine imaging modalities and strongly recommend their use in Hodgkin lym-
phoma and aggressive subtypes of Non-Hodgkin lymphomas for initial staging and verification 
of the disease remission. The benefit of PET and PET/CT in early mid-treatment restaging, their 
impact on long-term disease remission and overall patient survival has to be confirmed by 
ongoing clinical trials.
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P3. ENERGY RESOLUTION AND DETECTION EFFICIENCY 
OF CSI(TL) CRYSTALS WITH A HIGH CONCENTRATION 
ACTIVATOR FOR GAMMA RAY TOMOGRAPHY AND POSITRON 
EMISSION TOMOGRAPHY
C Madalina, I Cruceru
Department of Applied Nuclear Physics, Horia-Hulubei National Institute for R&D in Physics 
and Nuclear Engineering
An experimental analysis of energy resolution and detection efficiency is presented for scintillation 
crystals of thallium-activated cesium iodide (CsI(Tl) as a function of the activator (thallium) con-
centration. The analysis aim is to establish the optimal choice for this kind of crystals coupled to 
PIN photodiodes of large surface which will be used in performing of detection system for positron 
emission tomography device. These crystals have a high density,are non hygroscopic and can 
be manufactured at small dimensions which assure a good spatial resolution. The experimental 
detection efficiency of (30–65)% and the experimental energy resolution of (2.8–5.9)% at gamma 
radiation from 22Na, 137Cs and 60Co sources, were measured. The analysis has been conducted 
using crystals having Tl concentration larger than 1000 ppm.
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P4. BREAST CANCER PRESENTING AS A 18FDG/PET 
INCIDENTALOMA IN A PATIENT WITH INTESTINAL GIST
Silvia Cseriová
Oncological Institute of St. Elizabeth, Clinic of Nuclear Medicine Heydukova 10, 812 50 Bratislava Slovakia
Inroduction: 18FD/GPET imaging is widely used in clinical oncology. 18FDG/PET imaging 
is a clear advance in the approach to staging and monitoring breast cancer. Positron imaging 
offers better accuracy than conventional imaging in the identification of metastatic disease both 
in the initial staging of breast cancer and in follow-up. 
Case report: We describe the case of a 65 year old women who presented with GIST. 18FDG/PET 
was done for the follow up the treatment with Glivec. We revealed a low metabolic rate (SUVmax 
— 1,9) in upper left quadrant in left breast. The patient underwent mamography, follow core-cut 
biopsy, that revealed breast carcinoma corresponding to the lesion visualised on FDG/PET. 
Appearance of breast carcinoma during the routine control of patient with GIST was observed. 
A relationship between breast carcinoma and GIST has been not yet previously proposed.
Conclusion: This is a rare description of a concomitant breast carcinoma presenting as a FDG/PET 
incidentaloma alongside GIST. Even discrete findings made in the course of the PET examination have 
to be examined further.
In the future, further refinements in scanner technology and new radiopharmaceuticals will likely result 
in better identification of smaller lesions. Dedicated breast PET/CT or PET/Mammography units show 
promise in improved detection in primary breast cancer, while also providing a method for image guided 
biopsy.
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P5. RELIABLE PRODUCTION OF BEYOND FDG PET 
ON A DISPOSABLE-BASED FULLY AUTOMATED PLATFORM 
IN A GMP SITE
C Gameiro1,B Lambert2, C Sauvage3,J Koziorowski4,Z Ilan6,A Schmitz6, R Freifelder7, 
U Ackermann7, HJ Tochon-Danguy7
1IBA Chemin du Cyclotron, 3 Louvain-La-Neuve/BE; 2IBA, 100 Executive Dr., Sterling, VA/US ; 
3IBA Pharma, Av.de l’Espérance, 1 Fleurus/BE; 4Herlev University Hospital Dep. Clinical Physiology, 
54 P1 Herlev/DK; 5Aposense Ltd, 5–7 Odem St., Petach-Tikva/IL; 6University of Pennsylvania, Dep. 
of Radiology, Philadelphia PA/USA; 7Austin Health, Centre for Nuclear Medicine and PET, Heidelberg/AU
Introduction: PET modality is one the most rapidly growing areas of medical imaging thanks to 
the availability of innumerous clinical centers with their own biomedical cyclotrons. To be able to 
cover the growing clinical demands, a flexible, reliable platform (IBA Synthera) was developed 
for a (c)GMP environment. Well-known conventional chemistry steps were fully automated al-
lowing the synthesis of multiple 18F-tracers beyond FDG.
Materials/Methods: The platform consists of a synthesizer and an HPLC. The synthesizer 
employs a disposable system (IFP, integrated fluidic processor) where the entire synthe-
sis takes place. The IFPs are named after conventional synthesis steps they are designed to 
perform: nucleophilic substitution, chromatography, alkylation, distillation, and reformulation. 
Only one IFP is needed for a single synthesis, but they can be connected in series for multi-step 
processes. 
Results: In this work, several 18F-labeled tracers were synthesized by nucleophilic fluorination: 
direct fluorination (SN2 and SNAr) and synthon chemistry. The former can be performed in one 
step (18F-FP-DTBZ1, 18F-fallypride1) or in two steps; fluorination followed by removal of protec-
tive groups (18F-FDG, 18F-FMISO1, 18F-FAZA2, 18F-FHBG1, 18F-FAcetate3, 18F-F-A853801, 
18F-ML-10, florbetaben). Synthons like 18F-FBM (fluorobromomethane), 18F-SFB4 (succinimi-
dylfluorobenzoate) were also synthesized and they may be coupled to adequate precursors via 
acylation, alkylation or amide formation. For instance, 18F-FCH5 synthesis; 18F-FBM synthon 
produced in the first step N-alkylates the precursor resulting in 18F-FCH. This example shows the 
system is able to carry out multi-step processes.
Table 1. Average decay-corrected yields of the tracers synthesized
Yield
[d.c.%] 
Yield
[d.c.%]
Yield
[d.c.%]
FLT* 26.5 FCH** 28 ML-10* 66
FMISO** 64 FAZA* 28 SFB** 82.5
Fallypride* 36.2 Florbetaben* 65 FHBG* 9
FBE* 23.7 FP-DTBZ* 6 F-A85380* 34.3
Discussion/Conclusion: In most cases, the crude synthesis product required HPLC purification 
(*) while for the others cartridge purification (**) was sufficient (Table 1). In every synthesis para-
meters were optimized with respect to precursor amount, reaction time, temperature and concen-
tration. In most cases synthesis time was < 60 min. even when HPLC purification was included. 
Good synthesis yields (Table 1), > 95 % radiochemical and chemical purity were obtained and were 
superior when compared to manual synthesis (yields at least doubled). Less radiation exposure, 
shorter synthesis time and stable yields are the other advantages versus manual synthesis. By simply 
adapting the recipe and by using adequate IFP the automated platform was able to consistently 
produce several tracers in high yields and suitable for human injection. 
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P6. APPLICATION OF COMPARTMENTAL MODELS FOR POSITRON 
EMISSION TOMOGRAPHY (PET) 
A Jung, K Matusiak
AGH University of Science and Technology, Department of Medical Physics and Biophysics, 
Krakow, Poland
The development of Positron Emission Tomography (PET) has been rather dynamic during last 
few decades. Additionally, the progress has been perceptible simultaneously in several areas like 
the technical structure changes of device resulting in the development of the sophisticated 
hybrids like PET-CT or PET-NMR, improvement of software, increase in the amount and type of 
the radiopharmaceutics. Those modern diagnostic tools have been created and are currently 
available and more common in diagnostic centres. This kind of imaging allows us to observe 
not only physiological processes but also biochemical and pharmacological changes [1]. 
Moreover, PET method is so-called “molecular imaging” characterized by high sensitivity and 
ability for quantitative measurement [2]. 
However, more diagnostic information and quantitative physiologic analysis may be obtained if 
additional software packages are applied. Compartmental models are the basis for tracer kinetic 
analysis in PET. Those models are mostly used for blood flow, oxygen metabolism, cerebral 
metabolic rate for glucose or receptor concentration estimations [3, 4].
The number of compartments for the model depends on its application. The common model 
consists of 3 tissue compartments (or 4 compartments), where there are respectively arterial 
blood, free ligand in tissue, specific binding and non-specific binding. The transport between 
compartments is described then by six rate constants, usually linearly related to the concentration 
changes. But the single tissue compartment model is also applied, eg. for blood flow measure-
ment by 15O labelled water. Similarly two tissue compartment model fits properly for [18F]FDG 
kinetics description. On the other hand a more complex multicompartment models like that of 
FDOPA metabolism analysis can be found [2]. 
Predictably, a series of general assumptions is necessary, some of them are common for all 
analysis like the instantaneous mixing within the single compartment, and the others depend 
on the experimental design and the statistical noise [3]. Then under appropriate conditions the 
system is described by a set of first order linear differential equations. 
It was pointed out that compartment models may have some limits of application, eq. when data 
have high temporal resolution or with highly extracted radiopharmaceuticals. However, it seems 
— that for a typical temporal resolution of PET exam, the use of a distributed model has no advan-
tage over a compartment model for PET receptor quantification [5]. 
Many compartment models have been applied so far for quantitative PET data evaluation and they 
are still under development, what is the most important conclusion — it seems that they are to play 
an important role in molecular imaging. 
References
1. Gunn RN, Gunn SR, Turkheimer FE, Aston JAD, Cunningham VJ. Positron emission tomography 
compartmental models: a basis pursuit strategy for kinetic modeling. Journal of Cerebral Blood 
Flow & Metabolism 2002; 22: 1425–1439.
2. Watabe H, Ikoma Y, Kimura Y, Naganawa M, Shidahara M. PET kinetic analysis — comparmental 
model, Annals of Nuclear Medicine 2006; 20: 583–588.
3. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. 
Journal of Cerebral Blood Flow & Metabolism 2001; 21: 635–652.
4. Muzic Jr RF, Cornelius S. COMKAT: Compartment Model Kinetic Analysis Tool. The Journal of 
Nuclear Medicine 2001; 42: 636–645.
5. Muzic RF, Saidel GM. Distributed Versus Compartment Models for PET Receptor Studies. IEEE 
Transactions on Medical Imaging 2003; 22: 11–21.
A55www.nmr.viamedica.pl
Poster session Abstracts
P7. STAGING OF PRIMARY UTERINE CERVICAL NON-HODGKIN’S 
LYMPHOMA WITH FDG-PET/CT: A CASE REPORT
Dudu Kumptete
Turkey Association of Nuclear Medicine
Approximately one-fourth of the malignant lymphomas arise in extranodal organs. Primary non-Hodg-
kin’s lymphoma (NHL) of the female genital tract (FGT) is extremely rare. We report one case of 
primary extranodal NHL of the cervix. 
A 66-year old woman presented with postmenopausal vaginal bleeding. Vaginal examination 
revealed mass on the cervix. The cervical biopsy demonstrated diffuse large B-cell lymphoma. 
FDG-PET/CT for staging demonstrated a large cervical mass of 37 x 40 mm with uterine inva-
sion of increased FDG uptake (SUVmax: 24.9) as well as pelvic hypermetabolic (SUVmax: 21.0) 
conglomerated lymph nodes filling the pelvis.
The most common locations of primary extranodal NHL are gastrointestinal tract and skin. 
Primary NHL of the FGT is extremely rare (about 1.5%). Because of the rarity of lymphoma of 
the uterus and cervix, their staging, management and follow-up are not well defined. After the 
diagnosis, a complete physical examination searching for enlarged peripheral lymph nodes and 
chest, abdomen and pelvic CT scans along with bone marrow biopsy are required. Whole body 
imaging with FDG-PET/CT scan after the initial diagnosis can detect metastatic peripheral lymph 
nodes and bone marrow involvement. Therefore, FDG-PET/CT should be used in the initial work 
up of patients with cervical cancer for staging and management of surgery, radiotherapy and 
chemotherapy.
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P8. NOVEL 68GA-LABELED LYSINE DERIVATIVES OF OCTREOTIDE 
IN VITRO AND IN VIVO STUDY
A Larenkov, V Artyushkov, O Klementyeva, A Bruskin
Burnasyan Federal Medical Biophysical Center, Moscow, Russia
Introduction: Somatostatin receptors are over-expressed in most neuroendocrine tumors and 
other neoplasms (thyroid, breast, lung, etc). Radiolabelled somatostatin analogues are valuable 
tools for in-vivo diagnosis and therapy of neuroendocrine tumours (NET) due to the frequent 
tumoral overexpression of somatostatin receptors (sst). Clearance of a drug normally oc-
curs through the liver and kidneys and it is an important assumption that only free (i.e. not protein 
bound) drug is available for clearance. One of the decisive parameters is lipophilicity. This is the 
key physicochemical factor linking membrane permeability – and hence drug absorption and 
distribution — with the route of clearance (metabolic or renal). For radiopharmaceuticals the 
excretion pathways are of crucial importance for early and high tumor/background ratios and 
thus signal intensity in diagnostic by SPECT or PET and low toxicity for therapy. As pointed out 
above, the in vitro or the in vivo studies in animals can not always predict the drug ‘’perfor-
mance’’ in humans. In this study, we investigated biological behavior of the two somatostatin 
derivatives labeled with gallium-68 with different lipophilicity
Materials and methods: Derivatives of octreotide were synthesized by solid-phase method. 
They contain DOTA as a chelating group and lysine at various positions in the molecule. These 
compounds were tested in vitro by using cultures of mouse melanoma B16 and breast adeno-
carcinoma MCF 7 cell lines. As a control we used human lung fibroblasts cells (HLF).
In vivo experiments were carried out on melanoma-bearing mice C57Bl. All animal experi-
ments were conducted in compliance with the Russian animal protection laws and with the ethical 
principles and guidelines for scientific animal trials. For in vivo experiments F1 (CBA¥C57B1) 
female mice, 18–20 g body weight with melanoma B 16 were used. Experiments with mela-
noma-bearing mice were made in 9–10 days after inoculation when tumours had grown to 
approximately 1.5 cm in greatest diameter.
Results: For effective labeling (> 90%) of peptides was found conditions which were unique for 
each case. The results of in vitro experiments show that the studied compounds could specifically 
bind to tumor cells quite well.
The ability of sstr subtypes to undergo agonist-induced internalization is an important char-
acteristic of these receptors for transporting radiolabeled somatostatine analogs into the cell.
Figure 1. Cell uptake of 68Ga-DOTA-w-lysine-octreotide (A) and 68Ga-DOTA-a-lysine-octreotide (B)
A57www.nmr.viamedica.pl
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Our data show that both compounds are rapidly and almost entirely internalized by tumor cells, 
indicating that their receptor-specific capture. Maximum internalization (about 90%) achieved 
within 30 minutes after the start of incubation, which suggests the possibility of achieving suf-
ficient to render the level of accumulation.
Biodistribution data are shown in Table 1.
Discussion and conclusion: According to the biodistribution 68Ga-a-DOTA-lysine-octreotide some 
of its obvious advantages such as: more than 2 % ID/g tumor uptake, more than 10.6 muscle/tumor 
ratio and about 2 tumor/blood ratio after 60 min post injection. As the deficiencies should be noted 
the slow blood clearance and relatively high accumulation  in the liver and kidneys. On the other 
hand, 68Ga-w-DOTA-lysine-octreotide also has a number of advantages and disadvantages. The 
undoubted benefits of this compound include: rapid blood clearance, less accumulation in the liver, 
the value of tumor/blood ratio 4.3 after 60 min post injection, the values of tumor/muscle ratio 4.9 
after 60 min post injection. A disadvantage of this compound is to call it is not as strong binding 
and lower level of tumor accumulation.
Thus, DOTA-lysine octreotide derivates can be studied in future research as tumor seeking 
agents.
Table 1. Biodistribution of labeled compounds in melanoma B16 bearing mice (% of I.D.) 
        68Ga-a-DOTA-lysine-octreotide 68Ga-w- DOTA-lysine-octreotide
Time after 
injection, min
20 60 20 60
Blood 2.4 ± 1.2 0.5 ± 0.3 1.2 ± 0.3 0.3 ± 0.1
Liver 5.6 ± 3.7 5.3 ± 2.7 1.8 ± 0.2 1.0 ± 0.1
Kidneys 7.2 ± 1.7 5.1 ± 0.8 3.7 ± 1.1 5.3 ± 1.0
Muscle,% / g 0.7 ± 0.2 0.4 ± 0.2 1.3 ± 0.5 0.2 ± 0.1
Tumor, %/g 2.4 ± 0.03 4.0 ± 2.8 2.9 ± 0.7 1.1 ± 0.02
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 P9. C-11 LABELLED RADIOPHARMACEUTICALS FOR ROUTINE USE
P Mikecz, T Miklovicz, E Németh, I Jószai, D Szikra, N Pótári, G Pintér, L Galuska, L Trón
University of Debrecen, Medical and Health Science Centre, Department of Nuclear Medicine
Introduction: Carbon-11 is ideal radionuclide to apply in positron emission tomography due to 
its chemical and physical properties. Practically all the biologically active compounds containcarbon, 
only clever chemistry is required to replace one carbon-12 atom to carbon-11. Its half-life 20.4 mi-
nutes long enough to perform even sophisticated syntheses, and to make clinical investigations fea-
sible. The emitted positrons have 0.96 MeV energy what results 0.3 mm mean linear range, allowing 
good resolution in either human of preclinical PET investigations. In this presentation the production 
of three C-11 labelled radiopharmaceuticals: methionine, choline and PIB will be discussed.
Methods: The C-11 isotope was produced on a GE PETtrace cyclotron with the 14N(p, a)11C 
nuclear reaction, using high purity nitrogen gas containing 1% oxygen as target material. The 
resulting 11CO2 was converted into [11C]methyl iodide in gas phase using a PET trace MeIMi-
croLab module (GEMS, Uppsala. Sweden). This was used for the subsequent radiochemical 
syntheses performed on in house built synthesis modules. 
L-[11C-methyl]methionine was prepared by the methylation of L-homocysteine by [11C]me-
thyl-iodide in the presence of KF/Al2O3 catalyst, as was described earlier by Smitz et al. and 
more recently by Mitterhauser et al..Because during the routine production runs, unexpected 
impurities was detected (Szikra et al.) a new SPE purification step had to be introduced. The 
product was absorbed on a cation exchange column, the impurities were washed out, and the 
pure material was eluted.
[11C]cholinewas produced by the on-column method, first described by Pascali et al., then 
modified by Sher et. al. In this case the methylation of dimethyl amino ethanol took place on 
a SepPak column, from where after washing with ethanol and water the [11Cl]choline was eluted 
by saline solution without any further purification. 
For producing [11C]PIB([N-Methyl-11C](4’-methylaminophenyl)-6-hydroxybenzothiazole) the 
methyl iodide was converted into methyl triflate, which reacted with theprecursor in methyl 
ethyl ketone in sot time at moderate temperature (2 minutes , 80 oC). The product molecule 
was separated from the reaction mixture on a semipreparative column (Licrospher 100 RP18, 
10µm (Merck) with 0.1 N ammonium formate pH = 4: acetonitrile eluent.
Quality control methods were developed and implemented for all these radipopharmaceuticals, 
including HPLC and GC measurements.
Results and discussion: With these syntheses useful amount of radiopharmaceuticals has been 
produced for either routine or experimental use. In a typical run with irradiation of target at 45 µA 
for 20 minutes 6–12 GBq[11C]methionine or [11C]choline was produced. The radiochemical purity 
of [11C]cholinewas always < 99.9%. In case of [11C]methionine the average radiochemical purity 
is 98 %, however in several cases it was below the allowed 95%, and also the presence of iodide 
ions was noticed. Therefore a purification step had to be inserted in the procedure applying a cation 
exchanger. The evaluation of the effect of purification is under progress. Applying the same condi-
tions 1000 ± 200 MBq of [11C]PIB was obtained with a radiochemical purity > 95% and the specific 
activity of 120 ± 20 GBq/ µmol at the end of synthesis.
In Hungary marketing authorization is required for routine use of any radiopharmaceuticals, what 
makes the access to these very difficult. The department has obtained marketing authorization 
for [11C]methionine and currently is applying for [11C]choline. The [11C]PIB would be used only 
for clinical studies after the IMPD has been approved. 
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P10. NEW RADIOPHARMACEUTICALS RESEARCH CENTER (CCR) 
AT MAGURELE, ROMANIA 
D Niculae, I Ursu, L Craciun
Horia Hulubei National Institute for Physics and Nuclear Engineering (IFIN-HH) 
Department of Radioisotopes and Radiation Metrology, Magurele, Ilfov, Romania
The present status of IFIN-HH CCR (Radiopharmaceuticals Research Centre) project is reviewed 
and its development perspectives are addressed. 
The CCR benefits from a TR19 cyclotron (ACSI, Canada) with 4 external beam lines, dual par-
ticle irradiation (protons and deuterons), simultaneously dual target irradiation, variable energy 
(14–19 MeV for protons) for the production of commonly used PET radioisotopes (F-18, N-13, 
O-15, C-11, Pd-103, I-124 as well as research isotopes); hot cells, automated synthesis mo-
dules, automated dispenser, quality control laboratory and microPET.
At CCR are envisaged researches in the following areas:
— studies on new molecular targets (small molecules, antibodies, peptides, aptamers) showing 
specific and preferential uptake to tumor sites and other pathological processes labelled 
with positron emitters as potential PET radiopharmaceuticals;
— pharmacokinetics and pharmacodynamics of active subsatnces; testing of therapeutic 
properties and distribution, methabolism, elimination, toxicity studies of drugs using PET 
imaging;
— functional information and quantitative determination by fusion of images comming from dif-
ferent imaging techniques aiming volume corrections in small lesions, stadialization, global 
methabolic activity;
— production of Tc-99m through nuclear reaction 100Mo (p,2n) 99mTc for diagnosis and research 
in nuclear medicine;
— targetry developments.
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P11. STRIP-PET: CONCEPT OF TOF-PET SCANNER BASED 
ON POLYMER SCINTILLATOR STRIPS
P Moskal, T Bednarski, A Heczko, M Kajetanowicz, Ł Kapłon, A Kochanowski, 
G Konopka-Cupiał, G Korcyl, W Krzemień, K Łojek, W Migdał, M Molenda, Sz Niedźwiecki, 
P Salabura, M Silarski, A Słomski, J Smyrski, Z Rudy, J Zdebik, M Zieliński
Jagiellonian University, Cracow, Poland
The aim of the poster is to present an idea of a new PET scanner based on strips of polymer scintil-
lators arranged in a large acceptance detector system which may allow a simultaneous diagnostic 
of a large fraction of (or even the whole) human body. Detection chamber of PET made of plastic 
scintillators would be formed from strips of detectors as shown in Figure 1 [1]. Scintillation light from 
both sides of each strip is converted into electric signal by photomultipliers. In case of crystal detec-
tors for reconstruction one uses events from photoelectric effect, but in plastic scintillators probability 
for this phenomenon is negligible. Still it is possible to use events related to Compton effect inside 
the detector. The maximum energy deposition of electrons from the Compton edge is equal to about 
340 keV. Thus Strip PET with low energy threshold of 200 keV will reduce the scattering of gamma 
quanta in the body of a patient to the same extent as it is in the currently used tomographs which 
typically use the low energy threshold of 300 or 350 keV [2].
In Figure 2 we show Compton scattered electron energy distributions for the energy of gamma 
quanta reaching the detector without scattering in the patient’s body, after the scattering through 
an angle of 30 degrees and an angle of 60 degrees. The presented distributions show that in order 
to limit registration of quanta scattered in the patient to the range from 0 to 60 degrees (as used 
in the currently produced tomographs) one has to use an energy threshold of about 200 keV. To 
compensate for low density of plastic scintillators several layers of strips could placed around 
a patient [3] as it shown in Fig.3. The total thickness of cylinders of 5 cm results in efficiency of 
20% when requiring signals with energy deposits larger than 200 keV.
Novelty of the concept lies in employing predominantly the timing of signals instead of their 
amplitudes. The solution proposed will allow for the determination of position and time of the 
reaction of the gamma quanta based on the time measurement. The hit position versus the 
center of the scintillator (∆l) is determined based on time difference measured on both sides of 
the scintillation strip. The time at which gamma quantum hits the module can be determined 
Figure 1. Detector arrangement in plastic scintillator PET. Patient would lie inside the barrel, along scintillator 
strips
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Figure 2. Energy distribution of electrons scattered in the Compton effect by gamma quanta with an energy 
shown in the plot. The distributions were made without taking into accout the energy resolution, which for 
the strip detector readout on both sides isabout 18% (compared to LSO blocks which energy resolution is 
about 12%[4])
Figure 3. Two layer version of scintillation barrel
Figure 4. Schematic illustration of a new PET concept — Strip PET
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as an arithmetic mean of times measured on both sides of the module. Position (∆x) along the 
line of response is determined from time difference between two modules [4].
Reference
1. Moskal P. Patent Application No: P 388 555 [WIPO ST 10/C PL388555] (2009), PCT/PL2010/00062 
(2010).
2. Humm JL, Rosenfeld A, Del Guerra A. From PET detectors to PET scanners. Eur J Nucl Med 
Mol Imaging 2003; 30: 1574–1593.
3. Moskal P, Niedzwiecki S, Silarski M, Smyrski J, Zdebik J, Zieliński M. Novel detector systems 
for the Positron Emission Tomography. Bio-Algorithms and Med-Systems 2010, supl.; 6: 142.
4. Saha G. Basics of PET imaging. Springer, New York 2010.
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P12. THE DIAGNOSTIC ROLE OF 18F-FDG PET/CT IN PATIENTS 
WITH NEUROENDOCRINE TUMORS
Strahinja Odalović, Vera Artiko 
Center of Nuclear Medicine, Clinical Center of Serbia, Višegradska 26, 11000 Belgrade, Serbia
Introduction: 18F-Fluoro-deoxy-glucose positron emission tomography — computed tomography 
(FDG PET/CT) is important hybrid imaging modality in evaluation and monitoring of oncology patients. 
Neuroendocrine tumors (NETs) are neoplasms that arise from various neuroendocrine cells. Nuclear 
medicine techniques are known to play important role in diagnosis and therapy of NETs. Although, 
glucose metabolism is usually low in these tumors, more aggressive and high grade NETs can have 
elevated glucose metabolism, where FDG PET/CT may provide significant information. The aim of 
this retrospective study was to evaluate the usefulness of FDG PET/CT in diagnosis and manage-
ment of patients with NETs, such as gastroenteropancreatic and pulmonary NETs, paraganglioma 
and medullary thyroid carcinoma (MTC). 
Patients and methods: Sixteen patients (8 male and 8 female, mean age 47.3 ± 12.20 years) 
underwent FDG PET/CT examination at Center of Nuclear Medicine, Clinical Center of Serbia in 
Belgrade. Patients were diagnosed with NET (n = 6), paraganglioma (n = 6) and MTC (n = 4). 
PET/CT scanning was performed for staging or restaging. All patients were submitted to a routine 
whole-body imaging (from the base of the skull to the mid-thigh) on hybrid PET/CT scanner Sie-
mens Biograph True 64, 90 minutes after intravenous injection of FDG. Images were evaluated by 
two nuclear medicine physicians and one radiologist, and were analyzed both qualitatively and 
semi-quantitatively by measurement of standard uptake value (SUV). Results of FDG PET/CT were 
reviewed retrospectively and compared to follow-up clinical data, including results of multi-slice 
computed tomography (MSCT), ultrasound and magnetic resonance imaging (MRI), or biochemi-
cal marker values and findings of other nuclear medicine techniques (111In-pentreotide, 131I-MIBG, 
99mTc(V)-DMSA scintigraphy). When available, histopathology results were used to confirm diagnosis. 
The minimal follow-up period was three months. 
Results: FDG PET/CT scan suggested presence of metabolically active disease in eight patients. Du-
ring clinical follow-up, in four of these patients stabile or progressive disease was observed, confirmed 
by new lesions seen on conventional imaging methods or high biochemical marker values. In one 
patient, with metastatic mixed lung adenocarcinoma/small cell NET, focus of high FDG metabolic acti-
vity was seen on the neck, suggesting active disease in lymph nodes. This patient underwent biopsy 
and disease progression was confirmed by histopathology, with dominant anaplastic component. In 
one patient with MTC and positive PET scan, histopathology of the cervical lymph nodes overruled the 
existence of disease. Two patients, who were suspected to have active disease on PET showed no 
signs of illness during follow-up and were considered disease free. Thus, PET/CT findings in these three 
patients were considered to be false positive. In eight patients no foci of metabolically active disease were 
described on PET/CT. One patient with MTC had enlargement of cervical lymph nodes during follow-up 
and was submitted to biopsy. Histopathology results showed the presence of MTC in two excised lymph 
nodes, suggesting that FDG PET/CT finding was false negative. Other patients with negative PET scan 
remained disease free during follow-up. Overall, positive predictive value of PET/CT was 62.5%, while 
negative predictive value was 87.5%.
Conclusion: Our results suggest that FDG PET/CT can have significant role in management of pa-
tients with neuroendocrine tumors. The negative predictive value of FDG PET/CT was high in our study, 
suggesting good prognostic value of negative scan and that the real benefit of this hybrid imaging 
method can be in excluding the presence of disease.
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P13. SYNTHESIS, RADIOCHEMICAL AND IN VITRO AND IN VIVO 
EVALUATION OF HER2/NEU-DERIVED PEPTIDE AS A POTENTIAL 
BREAST CANCER IMAGING AGENT
SM Okarvi, I Al-Jammaz
Cyclotron & Radiopharmaceuticals Department. King Faisal Specialist Hospital and Research 
Centre-Riyadh.
Objectives: The overexpression of HER2/neu on several human cancers including breast 
and ovarian cancer and the low expression of this tumor-associated antigen on normal tis-
sues makes it an attractive molecular target for the diagnosis and therapy of cancer. To de-
velop tumor antigen-based peptide for breast cancer imaging, we prepared and characterized 
a HER2/neu-derived peptide containing the following sequence: Acetyl-Gly1-Gly2-Cys3-Asp4-
Lys5-Nle6-Phe7-Gly8-Ser9-Leu10-Ala11-Phe12-Leu13-CONH2.
Methods: The peptide was prepared by solid-phase synthesis technique according to 
Fmoc/HBTU methodology and radiolabeled with Tc-99m by stannous/tartrate exchange labeling 
method. In vitro tumor cell-binding and cellular internalization studies were performed on SKBR3 
and MDA-MB-231 breast cancer cell lines and in vivo biodistribution was determined in healthy 
mice and nude mice induced with MDA-MB-231 xenografts. 
Results: The structure and purity of the tumor-associated antigen peptide was confirmed by mass spec-
trometry and HPLC. Radio-HPLC analysis showed that the peptide labeled efficiently with Tc-99m (> 
95%) and formed one radioactive compound. Tc-99m-HER2/neu displayed high resistant to cysteine 
transchelation and high metabolic stability in human plasma in vitro. The radiopeptide exhibited high 
affinity binding to SKBR3 and MDA-MB-231 cells with the Kd values of 9.55 ± 2.74 nM and 4.40 ± 1.08 
nM, respectively. The radioactivity internalized into SKBR3 and MDA-MB-231 cells was 35 ± 3.8% and 
38 ± 4.57%, respectively. In vivo biodistribution in normal mice is characterized by rapid clearance from 
the blood and excretion by both the renal and hepatobiliary routes. The uptake in the major organs (lungs, 
liver, stomach, kidneys, etc.) was low (< 6% ID/g) both at 1 and 4 h p.i. The radiopeptide showed mo-
derate tumor uptake (2.58 ± 0.62% ID/g) as early as 1 h p.i., which reduced to 1.48 ± 0.51% ID/g at 4 h 
p.i. in nude mice bearing breast tumor xenografts. The uptake in the tumor was always higher than the 
radioactivity in the blood and muscle.
Conclusions: This initial study towards the development of a peptide-based tumor imaging agent 
indicated that the HER2/neu-derived peptide possess certain favorable in vitro and in vivo proper-
ties and deserve further evaluation in order to determine the real potential of this new and attractive 
class of peptides for tumor imaging.
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P14. FIRST EXPERIENCE OF PET-CT APPLICATION IN UKRAINE
OG Oliinichenko1, AV Kholodna1, OI Lola1, OM Klusov1, MM Firsova2, DS Osynsky1
1Kyiv City Center of Nuclear Medicine
2National Medical Academy of Postgraduate Education, Radiology Department
Introduction: First Ukrainian PET-CT started to function in Kyiv City Center of Nuclear Medicine 
in September 2011. 18FDG was used for diagnostics purposes. That pharmaceutical was syn-
thesized in PET unit cyclotron.
Materials and methods: 230 patients with different oncology pathologies were investigated:
Discussion: Proved diagnosis — 138, new lesions (which was not detected by other methods) 
— 58, restaging — 55. Besides, PET-CT was used in 5 patients for radiotherapy planning.
Conclusions: We used PET-CT diagnostic in according to experience of our European col-
leagues. Our own experience proved high sensitivity of the method in oncology practice. In the 
nearest future after synthesizing new pharmaceuticals 11C we are going to broaden PET-CT 
diagnostic for other medical fields as well as for oncology practice.
Lung cancer 32
Breast cancer 53
Ovarian cancer 6
Uterine cancer 7
Vaginal cancer 3
Fallopian tube cancer 1
Cervical cancer 2
 Soft tissue cancer 6
Unknown primary 9
Prostate cancer 3
Thyroid cancer 3
Pancreatic cancer 7
Colorectal cancer 18
Stomach cancer 3
Esophegeal cancer 1
Bone cancer(sarcoma) 1
Lymphoma (non-Hodgkin s Hodgkin) 45
Melanoma 11
Head and Neck cancer 3 
Urinary tract cancer 13
Tumor of the mediastinum 3
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P15. A ONE-STEP AUTOMATED RADIOSYNTHESIS OF 18F-FECNT 
FROM MESYLATE PRECURSOR
J Pijarowska-Kruszyna1, A Jaron1, B Malkowski2, K Kasprzak2, A Kowalska2, A Kachniarz2, 
R Mikolajczak1
1National Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, Poland
2Oncology Centre prof. Lukaszczyk Memorial Hospital, Departament of Nuclear Medicine, 
Bydgoszcz, Poland
Introduction: Dopamine transporter (DAT) is critical to the regulation of dopamine neurotransmis-
sion and is decreased by Parkinson’s disease. The fluorine-18 labelled ligand 2-beta-carbometh-
oxy-3-beta-(4-chlorophenyl)-8-(2-fluoroethyl)-nortropane (FECNT) has promising properties and 
appears to be an excellent DAT imaging agent in human PET study. This radiopharmaceutical can 
be widely used in the diagnostics of the Parkinson’s and other neurological diseases. However, 
it hasn’t been used for routine clinical trials because of a very low radiochemical synthetic yield. 
A semi-automated synthesis of [18F]FECNT based on the two-steps has been developed with 16% 
decay corrected yield [1]. We hypothesize that N-[18F]fluoroalkylnortropane analogs could be syn-
thesized at hight yield by direct 18F-fluorination from N-mesylate precursors. This compound and 
non-radioactive FECNT as a standard for identification of [18F]FECNT by HPLC chromatography 
were synthesized in accordance with requirements for Investigational Medicinal Product (IMP) and 
a one-step automated synthesis of [18F]FECNT was developed.
Methods: Synthetic approach adopted to synthesis of FECNT standard and precursor was based 
upon the published procedures [2, 3] with some modifications. The essential feature of this route 
was the reaction of Grignard reagent with the critical intermediate anhydroecognine methyl ester, 
which was obtained from cocaine hydrochloride by hydrolysis in hydrochloric acid and estrification 
with methanol. 3-b-substituted tropane derivative obtained in Grignard reaction was subjected to 
demethylation [4]. Non-radioactive FECNT was prepared by direct N-(2- fluoroethyl) alkylation of 
analytically pure 3-b-substituted nortropane precursor. The alkylating agent, 2-fluoroethyl brosylate, 
was prepared from 2-fluoroethanol and 4-bromobenzenesulfonoyl chloride. The crude product 
was purified by recrystallization. Mesylate (MsOECNT) precursor was synthesized from 3-b-substitu-
ted nortropane precursor in two steps by N-hydroxyethylation with 2-bromoethanol and subsequent 
mesylation of the obtained alcohol with appropriate anhydride and purified by preparative HPLC.
Automated synthesis of [18F]FECNT was carried out using 18F-multifunction synthesizer (Syn-
Chrom, Raytest). The [18F]fluoride was produced with 11MeV negative–ion cyclotron by the 
18O(p,n)18F reaction, trapped on QMA cartridge and eluted by solution containing: Kryptofix 
(K222) in CH3CN and 0.1 M K2CO3. The obtained complex K[
18F]FK2.2.2 was heated with mesylate 
precursor in CH3CN at 80°C for 15 min. The crude product [
18F]FECNT was purified by pre-
parative HPLC and C18 SepPak extraction. Analytical HPLC with UV and radiometric detection 
was used to assess the radiochemical purity and [18F]fluorination yield. 
Results: In the present study we investigated and optimized synthetic route of non-radioactive 
FECNT and developed an automated radiosynthesis of [18F]FECNT. Overall production yield was 74% 
for FECNT standard and 81% for MsOECNT synthesis and a purity of these products was over 
99% measured by the analytical HPLC (UV, 220 nm). The 1H NMR and MS analysis confirmed the 
structure of both compounds. Crude product [18F]FECNT was prepared with [18F]fluorination yield 
of > 70%. After purification, the final product was obtained with a radiochemical purity of > 99%. 
The radiochemical yield calculated from the beginning of the synthesis was 58% with decay cor-
rection. The duration of the total synthesis procedure was 80-90 min.
Conclusions: The reported one-step radiosynthesis, purification and dose formulation of final prod-
uct will provide a facile and reliable method for the production of high purity [18F]FECNT suitable for 
human use. In the future radiosynthesis of [18F]FECNT from tosylate precursor will be investigated.
References
1. Voll RJ et al. Appl Rad Isot 2005; 63: 353.
2. Zirkle CL et al. J Org Chem 1962; 34: 1269.
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P16. RADIOLABELING AND IN VITRO EVALUATION OF SHORT 
PEPTIDES THAT HAS A POTENTIAL AS ANGIOGENESIS 
IMAGING RADIOTRACERS
Mohammed Al-Qahtani, Yousif Al-Malki
Cyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research 
Center-Riyadh 11211, P.O. Box 3354 (MBC # 03), Saudi Arabia
Introduction: The growth of new blood vessels (angiogenesis) sustains tumor spread and growth 
or metastasizes by supplying oxygen and nutrients. Angiogenesis has been identified as a target 
site for therapeutic intervention because of its important role in tumor growth, metastasis, and 
inflammatory diseases. Angiogenesis is regulated by both activator and inhibitor molecules. An-
giogenesis is an equally important component of certain normal physiological processes such 
as embryogenesis, wound healing, and the female reproductive cycle.  The basement membrane 
(BM) is a delicate cell-associated sheet-like extracellular matrix and covers the basal aspect of all 
epithelia and endothelia. It surrounds muscle, fat, and peripheral nerve cells. 
Molecular markers for angiogenesis such as vascular endothelia growth factor receptors (VEG-
FRs) and the integrins (e.g. avb3) have become the logical targets for investigation. The inte-
grins are expressed and upregulated during angiogenesis. The receptors are known to bind 
peptides containing the arginine, glycine, and aspartic (RGD) amino acids sequence. This small 
peptide has been investigated extensively. Additionally the radiolabeled (F-18, Tc-99m, In-111, 
and Cu-64) analogs are being investigated as tracers for noninvasive measurement of angio-
genesis. These agents have shown promise in both animals and human patients. Therefore 
there is need to develop imaging methods that would measure the actual process at the 
molecular level. Additionally several VEGFR-2 antagonists have been identified based on the 
quinolyoxy-phenyl and quinazolin-4-yl pharmacophore. 
In this study monomeric C8 peptide and a number of its derivatives, labeled with 123/125/131I and 
in some cases 18F and then evaluated using human umbilical vein endothelial cells (HUVEC) 
cell line for in vitro.
Methods: All needed reagents and solvents were purchased and used with no further purifica-
tions unless its necessary. Reaction progress was monitored using both Radio-TLC and HPLC. 
The eluent was monitored with a variable-wavelength detector and a flow-through sodium iodide 
scintillation NaI(Tl) radioactivity detector. Radioactivity determined with a dose calibrator. The 
targeted peptide was radioiodinated applying the direct electrophilic method using either chlora-
mine-T or Iodogen as an oxidant reagent. For fluorination the 2,5-dioxoazolidinyl-4-fluorobenzoate 
(SFB) was used as labeling agent in a direct conjugation process.
Figure 1. Radio-HPLC of the radiofluorination reaction for a short C8 peptide and Radio-TLC for the collected peak; 
showing quantitative labeling
A69www.nmr.viamedica.pl
Poster session Abstracts
Results: The radiosynthesis and characterization results as well as initial biological evaluation 
will be presented.
Conclusions: The preliminary results indicates that short peptides of the C8 derivatives that 
been tested are promising imaging tracers of the angiogenesis biological process. 
Research support: This work was supported by King Abdualaziz City for Science & Techno-
logy (AT-29-15).
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1. Al-Qahtani M, Al-Khyat Z. Radiolabeling and In vitro evaluation of laminin derivatives that blocks 
angiogenesis and tumor growth. J Label Compd Radiopharm 2011; 54: S209.
2. Lourdes Ponce M et al. Identification of a Potent Peptide Antagonist to an Active Lamini-1 Se-
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Figure 2. Examples of the Saturation binding studies
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P17. CENTRE FOR BIOLOGICAL AND CHEMICAL SCIENCES 
NEW POSSIBILITIES IN PRECLINICAL RESEARCH USING PET, 
SPECT AND CT TECHNIQUES
Zbigniew Rogulski
University of Warsaw, Faculty of Chemistry, Warsaw, Poland
The Positron Emission Tomography (PET) is a method of nuclear medicine allowing non-invasive 
diagnostics of many diseases of internal organs. Oncology is one of the fields of clinical medicine 
where application of PET expands rapidly. The PET allows early and accurate tumor detection 
as well as enables direct monitoring of progress in the oncological treatment. There is also 
a growing interest in application of PET method, combined with SPECT and CT techniques, 
in the research related to the metabolism of practical drugs, e.g. those used in treatment of 
diseases of the nervous and cardiological systems. Simultaneously to clinical applications, PET 
technology for small animal imaging (animalPET), is one of the quickest developing diagnostic 
methods used in preclinical investigations of new radiopharmaceutics and in studies of the 
metabolism of drugs.
In 2009 The University of Warsaw has signed a contract with the Ministry of Science and Higher 
Education (Poland) to build a new research centre. The joint project of the Faculties of Biology and 
Chemistry of the University, called the Centre for Biological and Chemical Sciences (CENT III), will 
be located at the Ochota Campus on the ground floor of the Radiochemistry Department. CENT 
III will perform the function of a modern technology centre, conducting research and development 
activities connected with the areas of modern technology within the scope of the faculties. These 
areas are strategic from the point of view of national development and include biotechnology, 
biomedical technologies, environment protection, chemical sciences and new materials applied 
in medicine and various branches of industry. One of the most important R&D areas of the new 
Centre will be investigation of biologically active chemicals on small animals, including genetically 
engineered animals. Two laboratories of The Faculty of Chemistry of The University of Warsaw: the 
Laboratory of Electrochemical Power Sources and Laboratory of Biomolecules established a team 
with the purpose of setting up the first animalPET scanner in Poland. A new Laboratory of Molecu-
lar Imaging will be equipped with a variety of modern scientific tools required in PET experiments, 
including a high resolution multimodality imaging system using PET, SPECT and CT techniques, 
automatic synthesis units for nucleophilic and electrophilic substitution, hot cells, a quality control 
system, equipment necessary for synthesizing isotope labeled compounds and full anaesthesia 
system used in small animals research. The laboratory will be opened by the middle of 2012.
The Laboratory of Molecular Imaging will provide a modern research space for scientists of the 
Ochota Campus interested in investigation of biologically active chemicals on small animals. We 
hope that our knowledge and unique equipment will help emerging novel ideas and will allow ac-
complishment of many scientific goals. Convenient location of the laboratory, which will be close 
to many R&D institutions, e.g. the Nencki Institute of Experimental Biology (Polish Academy of 
Sciences), the Mossakowski Medical Research Centre (Polish Academy of Sciences), the Warsaw 
Medical University, and the Heavy Ion Laboratory of the Warsaw University, will allow us to establish 
strategic cooperation and will create flexible facility for preclinical investigation of new drugs. 
In April, 2012 the University of Warsaw and Carestream Health, Inc., will sign a Letter of Intent to 
establish mutual cooperation for the  development of molecular imaging techniques. The parties de-
clare to create at the University of Warsaw, at the Centre for Biological and Chemical Sciences, 
a Center of Excellence & a Reference Site for Carestream Molecular Imaging and their Albira and 
Multispectral digital imaging instruments. The cooperation will include:
— Opening the regional Centre of Excellence focused on the development of molecular imag-
ing techniques as modern tools in preclinical research, especially: Positron Emission Tomo-
graphy (PET),Single Photon Emission Computed Tomography (SPECT), Luminescence and 
Fluorescence techniques. 
— Improvement of the scientific qualifications of the personnel of the Centre of Excellence at 
the University of Warsaw.
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— Organizing scientific conferences, trainings and demonstrations.
— Promotion of new Carestream equipment used for preclinical research. 
— Cooperation in scientific projects focused on investigation of new biologically active com-
pounds.
Acknowledgements
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P18. PET/CT WITH 11C-ACETATE VERSUS 18F-FDG IN PATIENTS 
WITH RECURRENCE BIOCHEMISTRY OF PROSTATIC CARCINOMA
Juan Soto Andonaegui 
Nuclear Medicine, Mexico City, Mexico
Introduction: The prostate canceris the leading cause of mortality in the groupof malignan-
cies in men in Mexico, considered a public health problem in this population group. The he-
terogeneous spectrum of this neoplasm shows a marked increase in mortality,the foregoing 
marks a change in epidemiological trends in our country in recent years. Patients treated with 
curative intent have biochemical relapse probability of 15% to 40% at 5 years and about 70% in 10 
years, a fact which leads to the importance of imaging techniques that provide timely information 
on the evaluation of this neoplasm in subclínical stages. There is currently no diagnostic test to 
detect early and effective recurrence of this disease, even before the evidence of biochemical 
progression at low levels of Prostate Specific Antigen (PSA) from > 0.2 ng/ml, so we feel the 
need to study the potential of Positron Emission Tomography and Computed Tomography with 
the use of specific radiotracers, such as11C-acetate in patients with suspected recurrence of 
prostatic adenocarcinoma, the radiotracer internationally promises an exceptional advantage 
in early detection of recurrence with value slow compared to other conventional imaging me-
thods and even PET /CT with18F-FDG.
The 11C-Acetate benefits offered are: Null urinary excretion, thus better visualization of the 
prostate bed, evaluation of alternative pathways to glycolysis, where its direct incorporation 
into the Krebs cycle, allows us to study the metabolism of fatty acids direct translation in the 
synthesis of membrane lipid, very important in prostate tumors whose growth substrate for 
glucose is not primarily.
Objective: To establish the usefulness and validity of PET /CT with 11C-Acetate as specificradi-
otracer in the assessment of patients with biochemical recurrence of prostate adenocarcinoma 
versus 18F-FDG.
Materials and methods: This prospective study was conducted analytical unit in PET/CT 
cyclotron of the Faculty of Medicine UNAM in the period May 2011 to January 2012. A total of 
31 patients diagnosed with prostate cancer, only those with defined biochemical recurrence 
of PSAvalues > to 0.2 ng/ml and no evidence of other imaging methods for localization of 
residual tumor.
The acquisition of the PET/CT studies were performed first with 18F-FDG and 1 to 2 days of 
11C-acetate. All studies were performed on the computer PET/CT BiographTruePoint64 Sie-
mens Medical Systems, with the protocol of ourdepartment. The image analysis was performed 
by two radiologists and two nuclear medicine specialists with extensive experience.
Results: A total of 31 male patients with mean age of 67, PSA levels ranged from 0.32 ng/ml to 214 
ng/ml,with an average of 18.9 ng/ml. 25 studies were identified positive (83.3%) with 11C-Acetate 
6 witha negative diagnosis (16.7%), whereas 18F-FDG identified 10 studies positive for malignancy 
(33.3%) and 21 negative (66.7%). Statistical analysis revealed a sensitivity of PET/CT with11C-ac-
etate of 88% with a specificity of 100% with a confidence level of 95%, PPV was 100% and NPV of 
66.67%,18F-FDG both the sensitivity observed was 45.4% with a specificity of 100%, calculated 
PPV are 100% and NPV of 42.86% in the assessment of recurrence. We calculated the correlation 
of evidence with respect to histopathological study was obtained kappa coefficient for PET/CT with 
11C-Acetate 0.73 (95% CI: 0.46–1.00), while for 18 F-FDG was 0.32 (CI: 95% from 0.10 to 0.54). 
Was performed to measure the consistency of the test according to the criteria of Landisand Koch, 
revealing a substantial strength of agreement for11C-Acetate and 18F-FDG median.
Lesions detected by both methods clearly show the advantage of 11C-acetate in the detection 
of local and distant disease.
Conclusions: PET /CT with 11C-Acetate conclusively shows greater sensitivity in detecting pros-
tate cancer recurrence, with a high degree of validity in comparison with 18F-FDG, supported 
by substantial agreement when compared with the results of histopathology, being statistically 
significant. As is helpful in monitoring patients with suspected relapse, leading to the imperative of 
its spread torelated specialists as an excellent diagnostic tool for early diagnosis of this disease.
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P19. PET/CT IN MALIGNANT MELANOMA
CA Stan 
Fundeni Clinical Institute, Nuclear Medicine Departament, Fundeni Street 258, District 2, 
Bucharest, Romania
Purpose: To assess the diagnostic performance of positron emission tomography/computed 
tomography (PET/CT) using 18F-fluorodeoxyglucose (FDG) for N- and M-staging of cutane-
ous melanoma. 
Materials and methods: This is a retrospective study who underwent FDG-PET/CT for sta ging of 
cutaneous melanoma at the last 50 patients (untill present). Whole-body FDG-PET/CT was per-
formed of about 60- 90 minutes postinjection of about 370 MBq FDG. Diagnostic accuracy for 
N- and M-staging was determined for CT alone, PET alone, and PET/CT. 
Results: PET/CT detected significantly more visceral and nonvisceral metastases than PET alone 
and CT alone. PET/CT imaging thus provided significantly more accurate interpretations regard-
ing overall N- and M-staging than PET alone and CT alone. Accuracy of PET/CT was significantly 
higher than that of PET and CT for M-staging and significantly higher than that of CT for N-Staging.
Conclusions: The diagnostic performance of FDG-PET/CT for N- and M-staging of melanoma 
patients suggests its use for whole-body tumor staging, especially for detection or exclusion 
of distant metastases. 
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P20. BONE MARROW INVOLVEMENT IN SARCOIDOSIS PATIENT 
DIAGNOSED BY 18FDG/ PET — CASE REPORT
Z Tomišková, S Cseriová, D Cích, I Makaiová, S Kovacova 
Oncologic Institute of St. Elizabeth, Bratislava, Slovakia
Background: Sarcoidosis is a chronic inflammatory disease of unknown cause cha-
racterized histologically by granulomas in affected tissues, that usually presents with 
mediastinal and hilar lymphadenopathy and with variable involvement of the lungs. Other 
organs may be involved, including the skin, kidneys, liver, salivary glands, and bone mar-
row. The reported incidence of skeletal involvement with sarcoidosis ranges from 3% to 
as much as 36%. Medical treatment often involves corticosteroid therapy or methotrexate, 
but in some cases spontaneous regression occurs. The degree of inflammatory activity 
and systemic distribution of the disease helps in determining appropriate treatment. In 
most cases, the diagnosis requires confirmation with biopsy. 
Case presentation: We report a story of a young woman with an advanced breast cancer, 
who underwent a 18FDG/PET scan to detect the site of relapse. In three subsequent stu-
dies we monitor the response of cancer therapy and also the response to corticosteroid 
therapy of sarcoidosis. In the first study we find the typically uptake known as a “lambda” 
pattern that relates to bilateral hilar involvement. In the second study we saw the good re-
sponse to corticosteroid treatment, but progression of breast cancer. In the last PET scan 
of this patient we reveal bone marrow involvement of sarcoidosis, that was later confirmed 
by aspiration biopsy.
Conclusion: In this report, we highlight the role od 18FDG/PET to assess bone marrow 
involvement and to monitor efficiency of corticosteroid treatment in sarcoidosis patients.
